

Title	RandomiSed clinical trial assessing Use of an anti-inflammatoRy aGent in attenUating peri-operatiVe inflAmmatioN in non-meTastatic colon cancer – the S.U.R.G.U.V.A.N.T. trial
Authors	Redmond, H. Paul;Neary, Peter M.;Jinih, Marcel;O'Connell, Emer;Foley, Niamh M.;Pfirrmann, Rolf W.;Wang, Jiang H.;O'Leary, D. Peter
Publication date	2018-08-06
Original Citation	Redmond, H.P., Neary, P.M., Jinih, M., O'Connell, E., Foley, N., Pfirrmann, R.W., Wang, J.H. and O'Leary, D.P., 2018. RandomiSed clinical trial assessing Use of an anti-inflammatoRy aGent in attenUating peri-operatiVe inflAmmatioN in non-meTastatic colon cancer–the SURGUVANT trial. BMC cancer, 18(1),[794]. DOI:10.1186/s12885-018-4641-x
Type of publication	Article (peer-reviewed)
Link to publisher's version	<a href="https://doi.org/10.1186/s12885-018-4641-x">https://doi.org/10.1186/s12885-018-4641-x</a> - 10.1186/s12885-018-4641-x
Rights	© 2018 The Author(s) - <a href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</a>
Download date	2023-05-07 18:17:36
Item downloaded from	<a href="http://hdl.handle.net/10468/8486">http://hdl.handle.net/10468/8486</a>



# UCC


**University College Cork, Ireland**  
 Coláiste na hOllscoile Corcaigh

RESEARCH ARTICLE

Open Access



# Randomised clinical trial assessing Use of an anti-inflammatory agent in attenuating peri-operative inflammation in non-metastatic colon cancer – the S.U.R.G.U.V.A.N.T. trial

H. Paul Redmond, Peter M. Neary, Marcel Jinih, Emer O'Connell, Niamh Foley, Rolf W. Pfirrmann, Jiang H. Wang and D. Peter O'Leary 

## Abstract

**Background:** Peri-operative inflammation has been extensively highlighted in cancer patients as detrimental. Treatment strategies to improve survival for cancer patients through targeting peri-operative inflammation have yet to be devised.

**Methods:** We conducted a multi-centre, randomised controlled clinical trial using Taurolidine in non-metastatic colon cancer patients. Patients were randomly assigned to receive Taurolidine or a placebo. The primary endpoint for the study was the mean difference in day 1 IL-6 levels. Secondary clinical endpoints included rates of post-operative infections and tumor recurrence.

**Results:** A total of 293 patients were screened for trial inclusion. Sixty patients were randomised. Twenty-eight patients were randomised to placebo and 32 patients to Taurolidine. IL-6 levels were equivalent on day 1 post-operatively in both groups. However, IL-6 levels were significantly attenuated over the 7 day study period in the Taurolidine group compared to placebo ( $p = 0.04$ ). In addition, IL-6 levels were significantly lower at day 7 in the Taurolidine group ( $p = 0.04$ ). There were 2 recurrences in the placebo group at 2 years and 1 in the Taurolidine group. The median time to recurrence was 19 months in the Placebo group and 38 months in the Taurolidine group ( $p = 0.27$ ). Surgical site infection was reduced in the Taurolidine treated group ( $p = 0.09$ ).

**Conclusion:** Peri-operative use of Taurolidine significantly attenuated circulating IL-6 levels in the initial 7 day post-operative period in a safe manner. Future studies are required to establish the impact of IL-6 attenuation on survival outcomes in colon cancer.

**Trial registration:** The trial was registered with EudraCT (year = 2008, registration number = [005570-12](#)) and ISRCTN (year = 2008, registration number = [77,829,558](#)).

**Keywords:** Inflammation, Colon cancer, Peri-operative, Metastasis, Recurrence

\* Correspondence: [donaloleary@rcsi.ie](mailto:donaloleary@rcsi.ie)

Surugvant Research Centre, Cork University Hospital, Cork, Ireland



© The Author(s). 2018 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

## Background

Peri-operative inflammation is a phenomenon that has been extensively highlighted in cancer patients as a potential therapeutic target [1–3]. Strong links have been demonstrated between the pro-inflammatory components of the peri-operative inflammatory milieu and their effects locally on residual tumor cell deposits and systemically on disseminated tumor cells [4–9]. However, treatment strategies aimed at potentially improving survival for cancer patients by targeting peri-operative inflammation have yet to be devised, with the majority of treatment strategies aimed only at the neoadjuvant and adjuvant period.

The peri-operative inflammatory response itself is vital for the healing process, however several components of the inflammatory cascade initiated by surgical trauma confer accelerant effects on residual tumor deposits [10–15]. In particular, the pro-inflammatory cytokine IL-6 has been demonstrated to act as a key mediator in tumor cell growth by upregulation of metastatic gene expression and further stimulation of down-stream pro-inflammatory cytokines and growth factor release [16]. Tumor derived IL-6 also acts as a chemoattractant to circulating tumor cells and facilitates self-seeding of disseminated tumor cells [17, 18]. Moreover, elevated levels of IL-6 carry prognostic implications in certain tumor phenotypes including colon cancer, with elevated IL-6 levels closely associated with increasing tumor size, tumor stage, presence of metastatic disease and reduced survival [19].

Up to 30% of non-metastatic colon cancer patients can develop distant metastases. In particular, 70% of metastases will occur within 2 years of the initial 'curative' operation. This pattern is thought to relate to the effects of surgical inflammation [20, 21]. The best illustration of this cause-effect relationship is demonstrable where complications such as anastomotic leakage occur or where conversion from laparoscopic to open surgery is necessary [22]. In these scenarios patients experience a more exaggerated inflammatory response and ultimately have a worse outcome [23, 24]. Thus, colon cancer offers an ideal model to investigate the potential therapeutic effects of targeting inflammation.

To explore the concept of attenuating inflammation safely in cancer patients undergoing major surgery we chose the ubiquitously active agent Taurolidine which has been extensively studied in a variety of clinical states involved in inflammation and cancer with a remarkable safety record [25]. Taurolidine itself possesses both anti-inflammatory and anti-neoplastic properties and has an excellent safety profile [26–28]. Our pre-clinical experience of the anti-inflammatory effects of Taurolidine were in an experimental pancreatitis model where Taurolidine reduced the endotoxin levels in an animal model [29]. Other groups have shown a reduction in pro-inflammatory mediators including IL-1 and TNF- $\alpha$

associated with Taurolidine administration [30]. In addition, our group has demonstrated previously in the setting of a randomised clinical trial that peri-operative IL-6 can be safely and successfully targeted using this anti-inflammatory agent in patients undergoing coronary artery bypass surgery [31].

On this basis we hypothesised that peri-adjunctive utilisation of a dual anti-inflammatory and anti-neoplastic agent, Taurolidine, could potentially reduce immediate peri-operative inflammation which may confer survival benefits for colon cancer patients. Thus, to test this hypothesis, we performed a randomised, controlled clinical trial to examine the efficacy of using an anti-neoplastic agent on peri-operative inflammation in non-metastatic colon cancer patients undergoing resection of their primary tumor. We conceptualised the term 'surguvant' to define therapeutic modification used in combination with surgical treatment during the peri-operative period. We also sought to examine patient safety peri-operatively and observe the effects of this treatment strategy on disease free survival.

## Methods

### Trial design

A randomised, multicentre, placebo controlled, open label clinical trial was performed. Three centres recruited patients including Cork University Hospital, Bons Secours Cork and Mercy University Hospital. Patients were randomised on a 1:1 allocation ratio to 2% Taurolidine infusions or to a placebo, given 4 times a day for a total of 4 days. A sealed envelope method was used for randomisation. Randomisation codes were generated from [www.randomization.com](http://www.randomization.com).

The investigational medicinal product was an intravenous formulation of 2% Taurolidine ( $C_7H_{16}N_4O_4S_2$ ) manufactured by Geistlich-Pharma AG, CH 6110 Wolhusen/Luzern, Switzerland. The comparator placebo was 0.9% saline. The Taurolidine solution required central administration and all patients randomised to receive Taurolidine had either a central line or a peripheral long line inserted prior to the operation. First dose of Taurolidine or Placebo was administered at induction of anaesthesia. Trial bloods were performed pre-operatively, and at 3 h, 6 h, day 1, day 2, day 3, day 5 and day 7 (only if still an inpatient) post-operatively. Human IFN- $\gamma$ , IL-1 $\beta$ , IL-2, IL-6, IL-10, TNF- $\alpha$ , Human VEGF, Human CRP levels were measured using a customised ELISA kit manufactured by MSD (Meso Scale Discovery)\* (Gaithersburg, Maryland, US).

### Inclusion/exclusion criteria

Inclusion criteria included males and females between 18 and 85 years of age with non-metastatic colon cancer. Patients undergoing elective surgery only were included.

Exclusion criteria were as follows - Rectal cancers (defined as a tumor < 15 cm from the anal verge), patients with a known allergy to taurolidine / taurine, pregnant and lactating women, evidence of underlying liver disease (abnormal LFT's ( $> \times 2$  normal), INR  $> 1.5$ ), evidence of underlying renal disease (creatinine  $> 180$  for women,  $> 150$  for men), blood dyscrasia (neutropenia  $< 1500$  cells /cm<sup>3</sup>, thrombocytopenia  $< 100,000$  cells/cm<sup>3</sup>), evidence of intestinal obstruction, metastases (M1:Distant spread or Dukes D), morbid obesity (body mass index  $> 40$  kg/m<sup>2</sup>), operative risk  $> \text{ASA} - \text{III}$ , previous cancer / malignant disease other than non-melanoma skin cancer, coexisting active inflammatory disorder (including active RA, IBD, SLE), corticosteroids usage, immunosuppressive drugs, previous diagnosis of HIV, chronic active Hepatitis B or C (testing not required for study), active infection at the time of surgical intervention.

### Endpoints

The primary endpoint for the study was the difference in mean plasma IL-6 levels on day 1 in Taurolidine as compared to placebo group, adjusted for pre-operative IL-6, age and gender. Secondary laboratory endpoints included the difference in mean IL-6, IL-10 and CRP measured on post-operative days 2, 3, 5 and 7 in the Taurolidine as compared to the placebo group, adjusted for baseline measurement, age, gender and procedure type.

Exploratory analyses were conducted examining levels of TNF- $\alpha$ , VEGF, IL-1 $\beta$ , IFN- $\gamma$ , surface expression of CD14 and CD11b on neutrophils/monocytes, and plasma levels of C-reactive protein at the above time points.


Secondary Clinical Endpoints included a comparison of Taurolidine to control group with regard to occurrence & severity of post-operative infections, time to bowel functional recovery, post-operative pain control and recurrence (defined as local or metastatic growth) of tumor growth.

### Trial oversight

All patients provided full written informed consent. Trial participation was approved in all 3 study sites by the Cork Research Ethics Committee and the Irish Medicines Board and was registered with EudraCT (registration number = 2008-005570-12) and ISRCTN (registration number = 77,829,558). The trial was conducted in accordance with the provisions of the Declaration of Helsinki. A trial monitor was utilised to ensure the accuracy of the data collected and the case report form from each patient.

### Sample size

Precise sample size and power estimation for the trial was limited by lack of data within available literature describing expected baseline and follow-up levels of the various biochemical outcome parameters in the



proposed study population and lack of available evidence regarding the efficacy of the intervention within this setting. Based on the changes in IL-6 levels following colonic resection observed by Salvadora Delgado, M.D. et al. [32], we estimated that 28 patients in each arm would allow us to detect a 0.75 SD difference in study arms with 80% power, given a type 1 error rate of 5%, using a two sample t-test with equal samples sizes and a shared variance.

### Statistical analysis

Categorical data were described by their counts and percentages in each category. Continuous variables were described by their medians and inter-quartile ranges. All continuously measured laboratory endpoints were log transformed. Differences between study arms for laboratory endpoints, at each time point specified in the protocol, were estimated using ANCOVA, with adjustment for baseline measurement, age, sex, and procedure. Differences between study arms in linear trajectories of laboratory endpoints across all time-points (days 1–7) were estimated using linear mixed effects models using a treatment arm by Time interaction term. These models were adjusted for age, sex, and procedure type. The statistical significance of the interaction was tested using the *p*-value from the likelihood ratio chi-squared test.

Differences between study arms for categorical clinical endpoints were assessed using the chi-squared test. Differences between study arms for time-to-recurrence and mortality were estimated using the Cox proportional hazards model, adjusted for age, sex, and procedure.

All analyses were conducted on an intent-to-treat basis, using the R Project for Statistical Computing (version 3.2.2 R Foundation for Statistical Computing, Vienna, Austria. [www.r-project.org/](http://www.r-project.org/)).

### Results

A total of 293 patients were screened for trial inclusion. Two hundred thirty three patients were excluded, thus 60 patients were randomised to either study group (Fig. 1). Twenty-eight patients were randomised to placebo and 32 patients to Taurolidine. The patient, tumor and operative characteristics are summarised in Table 1. There was no significant difference in these characteristics between the two study arms.

### Primary endpoint and post-hoc analysis

A peak in IL-6 levels in both study groups was evident at 24 h post surgery. The overall trend for this IL-6 peak was to settle over the remaining study days. IL-6 levels at 24 h were equivalent in the Taurolidine and placebo group ( $p = 0.89$ ). Post-hoc analysis was performed to analyse the selected study cytokines in both study groups over the entire 7 day study period (Fig. 2). IL-6 levels


**Table 1** Patient, surgery and tumor characteristics, reported as n(%), or median[IQR]

	Total (n = 60)	Saline (n = 28)	Taurolidine (n = 32)	<i>p</i> -value
Sex				
F	21 (35%)	6 (21.4%)	15 (46.9%)	0.07
M	39 (65%)	22 (78.6%)	17 (53.1%)	
Age	69 [59.8, 72.2]	67 [58.8, 72]	69.5 [65.2, 72.2]	0.49
Surgery				
Anterior resection	27 (45%)	12 (42.8%)	15 (55.6%)	0.55
Right hemicolectomy	23 (38.3%)	12 (42.8%)	11 (40.7%)	
Total colectomy	1 (1.7%)	0(0%)	1 (3.7%)	
Other	9 (15%)	4 (14.2%)	5 (15.6%)	
Procedure				
Converted	6 (10%)	3 (10.7%)	3 (9.4%)	0.59
Lap	47 (78.3%)	23 (82.1%)	24 (75%)	
Open	7 (11.7%)	2 (7.1%)	5 (15.6%)	
Primary tumor				
T1	4 (6.7%)	1 (3.6%)	3 (9.3%)	0.59
T2	8 (13.3%)	5 (17.8%)	3 (9.3%)	
T3	34 (56.6%)	16 (57.1%)	18 (56.2%)	
T4	8 (13.3%)	2 (7.1%)	6 (18.8%)	
T4a	4 (6.7%)	3 (10.7%)	1 (3.2%)	
T4b	1 (1.7%)	1 (3.5%)	0 (0%)	
Carcinoid	1 (1.7%)	0 (0%)	1 (3.2%)	
Regional lymph nodes				
N0	31 (51.6%)	12 (42.8%)	19 (59.4%)	0.37
N1	9 (15%)	5 (17.8%)	4 (12.5%)	
N1a	7 (11.6%)	4 (14.2%)	3 (9.4%)	
N1b	6 (10.0%)	3 (10.8%)	3 (9.4%)	
N2	5 (8.4%)	3 (10.8%)	2 (6.2%)	
N2b	2 (3.4%)	1 (3.6%)	1 (3.1%)	
Lymph node yield	17	16	18	0.58
Follow-up (months)	34	32	37	0.23

were found to be significantly attenuated in the Taurolidine group compared to the placebo group over the course of the study period ( $p = 0.04$ ). In addition, the mean levels of IL-6 were significantly attenuated in the Taurolidine group compared to placebo at 7 days ( $p = 0.04$ ).

### Secondary laboratory end-points

TNF- $\alpha$  levels demonstrated a peak at 24 h post surgery. The rate of TNF- $\alpha$  attenuation in Taurolidine treated patients compared to placebo over the 7 days approached



**Fig. 2** Seven-day linear trends in laboratory endpoints. Differences in the 7-day linear trend between treatment arms were tested using linear mixed effects models and treatment X time interaction term. The *p*-values in the plot are from the likelihood ratio test for a model including that interaction term vs. a model without it

significance ( $p = 0.07$ ). At the 7 day time point, IL-2 demonstrated a trend towards attenuation in the Taurolidine treated group compared to placebo ( $p = 0.06$ ). The remaining cytokines and growth factors did not show any significant changes over the study period between the two study groups.

### Secondary clinical end-points

The median length of stay was 6 days for the entire study cohort. There were 11 cases of post-operative infective complications. Six of the infective complications were surgical site infections, 5 cases were in the placebo group and 1 in the Taurolidine group ( $p = 0.09$ ) (Table 2). Three post-operative infections were anastomotic leaks, 2 in the placebo and 1 in the Taurolidine treated group ( $p = 0.41$ ). The remaining 2 infective complications consisted of a lower respiratory tract infection in a patient with underlying COPD and cellulitis at the site of PICC

line insertion. Both of these infective complications were in the Taurolidine group.

The mean time to return of bowel function was 39 h in the placebo group and 34 h in the Taurolidine group ( $p = 0.32$ ). Pain scores demonstrated no difference between the two study groups ( $p = 0.39$ ).

### Survival end-points

At the 2 year follow-up time point there were 3 recurrences in total, 2 in the placebo group and 1 in the Taurolidine group ( $p = 0.38$ ) (Table 3). The overall median follow-up at the time of data analysis was 34 months (range 24 months to 5 years). The median follow-up time in the placebo group was 32 months (range 24–76 months). The median follow-up time in the Taurolidine group was 37 months (range 24–76 months). In this time period 6 patients had experienced a recurrence, with 3 in the placebo treated group and 3 in the Taurolidine group ( $p = 0.64$ ). In these patients the median time to recurrence was 19 months in the placebo group and 38 months in the Taurolidine group ( $p = 0.27$ ). The 3 placebo group patients developed

**Table 2** A comparison of clinical end-point data

		Placebo (n = 28)	Taurolidine (n = 32)	<i>p</i> -value
Pain	Day 1	2.5	1.8	0.391
	Day 2	1.9	2	0.873
	Day 3	1.9	1	0.179
Time to bowel function (hrs)		39	34	0.32
Infective complication		8	4	0.19
Surgical site infection		5	1	0.09
Anastomotic leak		2	1	0.59
Other		0	2	0.49

**Table 3** A comparison of survival outcome data

	Total (n = 60)	Saline (n = 28)	Taurolidine (n = 32)	<i>p</i> -value
Overall recurrence	6	3	3	1
Recurrence at 2 years	3	2	1	0.389
Mean time to recurrence (months)		16.3	28.6	0.4
Median time to recurrence (months)		19	38	0.268



loco-regional recurrence. The 3 Taurolidine patients developed distant metastatic disease.

## Discussion

This multi-centre, randomised clinical trial was specifically designed to address the question of the potential effects of surgically induced inflammation on perioperative tumor kinetics using IL-6 as a surrogate marker. We used the agent Taurolidine to therapeutically modify these effects during the peri-operative time period. Although there was no difference seen at the early 24 h time-point, post hoc analysis demonstrated a significant trend for IL-6 attenuation over the 7 day post-operative period in Taurolidine versus the control group, with levels being significantly different at post-operative day 7. Thus whilst we do not demonstrate an immediate post-operative effect, in post hoc analysis we see a delayed effect from Taurolidine on circulating IL-6 levels.

The levels of circulating colon cancer cells and circulating colon cancer stem cells are significantly higher peri-operatively, particularly within the portal venous system [33, 34]. Together with a surge in circulating pro-inflammatory cytokine and growth factor levels, this is a significant and completely understudied phenomenon that potentially has detrimental implications for cancer patients in both the short and long term. This trial provides evidence, at least in part, that targeting the inflammatory response in particular can potentially reduce post-operative tumor metastatic growth resulting in improved patient survival outcome. In particular it can reduce inflammation and ultimately may improve patient outcome.

Circulating levels of IL-6 were attenuated in response to Taurolidine administration in a time dependent manner. It is possible that earlier administration of Taurolidine a number of days pre-operatively might result in a more immediate attenuation of IL-6 post-operatively. Furthermore, post-operative administration over an extended period of time may also have an added benefit in the presence or absence of chemotherapy [35].

IL-6 can propagate colon cancer cell growth and unsurprisingly circulating levels of IL-6 are prognostic in colon cancer [36]. The present study was not powered for a formal survival analysis so it is not possible to assess the clinical impact of IL-6 attenuation, however interesting trends are emerging from this data in relation to survival outcome. The median time to tumor recurrence was longer, though not significantly different in patients who were treated with Taurolidine versus those that were treated with placebo (38 months versus 19 months). However, these are only trends and would require an appropriately powered trial in order to draw solid conclusions.

Surgical patients are dependent upon components of inflammation to heal safely. Compromise of the healing process can lead to life-threatening complications, for example an anastomotic leak. Unsuccessful attempts at utilising the peri-operative period for adjunctive therapies have failed in the past due to compromise of safety. The present trial demonstrates that the anti-inflammatory agent Taurolidine can target key pro-inflammatory cytokines without compromising patient safety.

Several key points now need to be addressed. Firstly, does extension of the period of Taurolidine administration help to further attenuate pro-inflammatory responses to surgical trauma. Careful attention to patient safety and safety outcomes will be required if further extension of the administration period is considered. Secondly, does the attenuation of the inflammatory response translate into a survival benefit? We hypothesise that the attenuation of IL-6 levels over the initial post-operative week may lead to a clinically relevant improvement in patient outcomes as the peri-operative interaction of disseminated tumor cells and the pro-inflammatory milieu of cytokines/growth factors will occur in a less favourable environment. However this needs to be further addressed in a large, adequately powered clinical trial.

## Conclusions

Peri-operative use of Taurolidine attenuated circulating IL-6 levels in a progressive manner post-operatively. We believe that further investigation of such 'surguvant' therapies during this under-investigated period could lead to significant improvements in surgical patient outcomes in a safe manner.

## Abbreviations

ANCOVA: Analysis of covariance; ASA: American society of anaesthesiologists; CD-11b: Cluster of differentiation 11b; CD-14: Cluster of differentiation 14; COPD: Chronic obstructive pulmonary disease; CRP: C-reactive protein; HIV: Human immunodeficiency virus; IBD: Inflammatory bowel disease; IFN- $\gamma$ : Interferon gamma; IL-10: Interleukin 10; IL-1 $\beta$ : Interleukin 1-beta; IL-2: Interleukin 2; IL-6: Interleukin-6; INR: International normalised ratio; LFTs: Liver function tests; RA: Rheumatoid arthritis; SLE: Systemic lupus erythematosus; TNF- $\alpha$ : Tumour necrosis factor- $\alpha$ ; VEGF: Vascular epithelial growth factor

## Acknowledgements

A number of individuals contributed to this study and should be acknowledged for their efforts including Professor Mich  al O'Riord  in, Mr. Colm O'Boyle, Mr. David Gough, Professor Joe Eustace, Mr. Darren Dahly, Mr. Emmet Andrews, Mr. Morgan McCourt, Professor Mark Corrigan, Dr. Derek Power and Dr. Patrick Hallihan,

## Funding

The trial was funded by Geistlich Pharma AG, Wolhusen, Switzerland. The funding body had no role in data collection. Data analysis and interpretation was performed by a statistician who received support from the funding body. Accuracy of trial data was overseen by an independent trial monitor who was supported by the funding body. Study design and manuscript preparation was performed independent of the funding body.

## Availability of data and materials

Trial data is available from authors at request.

### Authors' contributions

HPR was involved in trial conception, design, manuscript preparation and final approval for publication. PN contributed to trial design and data collection. MJ contributed to data collection and data analysis. EOC contributed to data collection and data analysis. NF contributed to data collection and data analysis. RP contributed to trial design and manuscript preparation. JHW contributed to trial design, data analysis and manuscript preparation. DPOL contributed to trial design, data collection, data analysis and manuscript preparation. All authors read and approved the final manuscript.

### Ethics approval and consent to participate

Trial participation was approved in all 3 study sites by the Cork Research Ethics Committee and the Irish Medicines Board and was registered with EudraCT (registration number = 2008-005570-12) and ISRCTN (registration number = 77,829,558). Written consent to participate was given by each patient.

### Consent for publication

Participating patients gave full written informed consent to allow for patient data to be included in any subsequent publication.

### Competing interests

The authors declare that they have no competing interests.

### Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 19 February 2018 Accepted: 27 June 2018

Published online: 06 August 2018

### References

- O'Leary DP, O'Leary E, Foley N, Cotter TG, Wang JH, Redmond HP. Effects of surgery on the cancer stem cell niche. *Eur J Surg Oncol*. 2016;42:319–25.
- Coffey JC, Wang JH, Smith MJ, Bouchier-Hayes D, Cotter TG, Redmond HP. Excisional surgery for cancer cure: therapy at a cost. *Lancet Oncol*. 2003;4(12):760–8.
- Coffey JC, Smith MJ, Wang JH, Bouchier-Hayes D, Cotter TG, Redmond HP. Cancer surgery: risks and opportunities. *BioEssays*. 2006;28:433–7.
- O'Leary DP, Wang JH, Cotter TG, Redmond HP. Less stress, more success? Oncological implications of surgery-induced oxidative stress. *Gut*. 2013;62:461–70.
- Beecher SM, O'Leary DP, McLaughlin R, Sweeney KJ, Kerin MJ. Influence of complications following immediate breast reconstruction on breast cancer recurrence rates. *Br J Surg*. 2016;103:391–8.
- Al-Sahaf O, Wang JH, Browne TJ, Cotter TG, Redmond HP. Surgical injury enhances the expression of genes that mediate breast cancer metastasis to the lung. *Ann Surg*. 2010;252:1037–43.
- Coffey JC, Wang JH, Smith MJ, Laing A, Bouchier-Hayes D, Cotter TG, Redmond HP. Phosphoinositide 3-kinase accelerates postoperative tumor growth by inhibiting apoptosis and enhancing resistance to chemotherapy-induced apoptosis. Novel role for an old enemy. *J Biol Chem*. 2005;280:20968–77.
- Qadri SS, Wang JH, Coffey JC, Alam M, O'Donnell A, Aherne T, Redmond HP. Can surgery for cancer accelerate the progression of secondary tumors within residual minimal disease at both local and systemic levels? *Ann Thorac Surg*. 2005;80:1046–50. discussion 1050–1.
- Qadri SS, Wang JH, Coffey JC, Alam M, O'Donnell A, Aherne T, Redmond HP. Surgically induced accelerated local and distant tumor growth is significantly attenuated by selective COX-2 inhibition. *Ann Thorac Surg*. 2005;79:990–5. discussion 990–5.
- Coffey JC, Wang JH, Bouchier-Hayes D, Cotter TG, Redmond HP. The targeting of phosphoinositide-3 kinase attenuates pulmonary metastatic tumor growth following laparotomy. *Ann Surg*. 2006;243:250–6.
- O'Leary DP, Bhatt L, Woolley JF, Gough DR, Wang JH, Cotter TG, Redmond HP. TLR-4 signalling accelerates colon cancer cell adhesion via NF- $\kappa$ B mediated transcriptional up-regulation of Nox-1. *PLoS One*. 2012;7:e44176.
- Killeen SD, Wang JH, Andrews EJ, Redmond HP. Bacterial endotoxin enhances colorectal cancer cell adhesion and invasion through TLR-4 and NF- $\kappa$ B-dependent activation of the urokinase plasminogen activator system. *Br J Cancer*. 2009;100:1589–602.
- Beecher SM, O'Leary DP, McLaughlin R, Kerin MJ. The Impact of Surgical Complications on Cancer Recurrence Rates: A Literature Review. *Oncol Res Treat*. 2018;41(7-8):478–2.
- Ni Chioleain N, Redmond HP. Cell response to surgery. *Arch Surg*. 2006;141:1132–40.
- Wang JH, Manning BJ, Wu QD, Blankson S, Bouchier-Hayes D, Redmond HP. Endotoxin/lipopolysaccharide activates NF- $\kappa$ B and enhances tumor cell adhesion and invasion through a beta 1 integrin-dependent mechanism. *J Immunol*. 2003;170:795–804.
- Kumari N, Dwarakanath BS, Das A, Bhatt AN. Role of interleukin-6 in cancer progression and therapeutic resistance. *Tumour Biol*. 2016;37:11553–72. Epub 2016 Jun 3.
- Zhang Y, Ma Q, Liu T, Guan G, Zhang K, Chen J, Jia N, Yan S, Chen G, Liu S, Jiang K, Lu Y, Wen Y, Zhao H, Zhou Y, Fan Q, Qiu X. Interleukin-6 suppression reduces tumour self-seeding by circulating tumour cells in a human osteosarcoma nude mouse model. *Oncotarget*. 2016;7:446–58.
- Kim MY1, Oskarsson T, Acharyya S, Nguyen DX, Zhang XH, Norton L, Massagué J. Tumor self-seeding by circulating cancer cells. *Cell*. 2009;139:1315–1326.
- Olsen J, Kirkeby LT, Olsen J, Eiholm S, Jess P, Gögenur I, Troelsen JT. High interleukin-6 mRNA expression is a predictor of relapse in colon cancer. *Anticancer Res*. 2015;35:2235–40.
- Neary PM, Hallihan P, Wang JH, Pfirrmann RW, Bouchier-Hayes DJ, Redmond HP. The evolving role of tauridine in cancer therapy. *Ann Surg Oncol*. 2010;17:1135–43.
- Killeen SD, Andrews EJ, Wang JH, Wu T, Schmalix W, Muehlenweg B, Redmond HP. Inhibition of urokinase plasminogen activator with a novel enzyme inhibitor, WXC-340, ameliorates endotoxin and surgery-accelerated growth of murine metastases. *Br J Cancer*. 2007;96:262–8.
- Condon ET, Barry BD, Wang JH, Kirwan WO, Redmond HP. Laparoscopic surgery protects against the oncologic adverse effects of open surgery by attenuating endothelial progenitor cell mobilization. *Surg Endosc*. 2007;21:87–90.
- Huang SG, Li YP, Zhang Q, Redmond HP, Wang JH, Wang J. Laparotomy and laparoscopy diversely affect macrophage-associated antimicrobial activity in a murine model. *BMC Immunol*. 2013;14:27.
- Clancy C, O'Leary DP, Burke JP, Redmond HP, Coffey JC, Kerin MJ, Myers E. A meta-analysis to determine the oncological implications of conversion in laparoscopic colorectal cancer surgery. *Color Dis*. 2015;17:482–90.
- Ripps H, Shen W. Taurine: a "very essential" amino acid. *Mol Vis*. 2012;18:2673–86.
- Sun BS, Wang JH, Liu LL, Gong SL, Redmond HP. Tauridine induces apoptosis of murine melanoma cells in vitro and in vivo by modulation of the Bcl-2 family proteins. *J Surg Oncol*. 2007;96:241–8.
- Da Costa ML, Redmond HP, Bouchier-Hayes DJ. Tauridine improves survival by abrogating the accelerated development and proliferation of solid tumors and development of organ metastases from circulating tumor cells released following surgery. *J Surg Res*. 2001;101:111–9.
- McCourt M, Wang JH, Sookhai S, Redmond HP. Tauridine inhibits tumor cell growth in vitro and in vivo. *Ann Surg Oncol*. 2000;7:685–91.
- Redmond HP, Leahy AL, Carey JA, Darzi A, Maxwell B, Keane FB, Tanner WA. Beneficial effects of tauridine in experimental pancreatitis. *J Surg Res*. 1994;56(3):256–60.
- Bedrosian I, Sofia RD, Wolff SM, Dinarello CA. Tauridine, an analogue of the amino acid taurine, suppresses interleukin 1 and tumor necrosis factor synthesis in human peripheral blood mononuclear cells. *Cytokine*. 1991;3:568–75.
- Doddakula KK, Neary PM, Wang JH, Sookhai S, O'Donnell A, Aherne T, Bouchier-Hayes DJ, Redmond HP. The antiendotoxin agent tauridine potentially reduces ischemia/reperfusion injury through its metabolite taurine. *Surgery*. 2010;148:567–72.
- Delgado S, Lacy AM, Filella X, Castells A, García-Valdecasas JC, Pique JM, Mombán D, Visa J. Acute phase response in laparoscopic and open colectomy in colon cancer: randomized study. *Dis Colon Rectum*. 2001;44:638–46.
- Wind J, Tuynman JB, Tibbe AG, Swennenhuis JF, Richel DJ, van Berge Hegengouwen MI, Bemelman WA. Circulating tumour cells during laparoscopic and open surgery for primary colonic cancer in portal and peripheral blood. *Eur J Surg Oncol*. 2009;35:942–50.
- Katsuno H, Zacharakis E, Aziz O, Rao C, Deebea S, Paraskeva P, Ziprin P, Athanasiou T, Darzi A. Does the presence of circulating tumor cells in the



- venous drainage of curative colorectal cancer resections determine prognosis? A meta-analysis. *Ann Surg Oncol*. 2008;15:3083–91.
35. Guthrie GJ, Roxburgh CS, Farhan-Alanie OM, Horgan PG, McMillan DC. Comparison of the prognostic value of longitudinal measurements of systemic inflammation in patients undergoing curative resection of colorectal cancer. *Br J Cancer*. 2013;109:24–8.
36. Guthrie GJ, Roxburgh CS, Richards CH, Horgan PG, McMillan DC. Circulating IL-6 concentrations link tumour necrosis and systemic and local inflammatory responses in patients undergoing resection for colorectal cancer. *Br J Cancer*. 2013;109:131–7.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

